Back to ChemicalBook Home--->CAS DataBase List--->606143-52-6

606143-52-6

606143-52-6 Structure

606143-52-6 Structure
IdentificationBack Directory
[Name]

AZD 6244
[CAS]

606143-52-6
[Synonyms]

AZD 6244
Selumetinib
Array142886
ARRY 142886
AZD6244(SeluMetinib)
SeluMetinib (AZD6244)
selumetinib (MEK inhibitor)
AZD-6244(SeluMetinib)/AZD6244
AZD6244, ARRY-142886, ARRY-886
5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carbox
5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
5-(4-Bromo-2-chlorophenylamino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide
6-(4-Bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide
5-(4-BroMo-2-chlorophenylaMino)-4-fluoro-1-Methyl-1H-benziMidazole-6-carbohydroxaMic acid 2-hydroxyethyl ester
SeluMatinib(5-[(4-BroMo-2-chlorophenyl)aMino]-4-fluoro-N-(2-hydroxyethoxy)-1-Methyl-1H-benziMidazole-6-carboxaMide
AZD 6244 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide Selumetinib (AZD6244)
[EINECS(EC#)]

207-313-3
[Molecular Formula]

C17H15BrClFN4O3
[MDL Number]

MFCD11977472
[Molecular Weight]

457.685
[MOL File]

606143-52-6.mol
Chemical PropertiesBack Directory
[density ]

1.69
[pka]

14.20±0.10(Predicted)
[form ]

Beige powder.
Hazard InformationBack Directory
[Usage]

It is a tight-binding, uncompetitive inhibitor of mitogen-activated protein kinase kinases (MEK) 1 and 2 currently in clinical development.
[Description]

Selumetinib (AZD6244; ARRY-142886) is an oral MEK inhibitor. In a randomized trial, NSCLC patients with wild-type KRAS were randomized to erlotinib alone or combination therapy with selumetinib, while mutant KRAS patients were randomized to selumetinib alone or combination therapy. The primary end points were PFS for the KRAS wild-type cohort and objective response rate (ORR) for the KRAS mutant cohort. Results were not impressive, with no PFS difference in the KRAS wild-type arm (2.4 vs. 2.1?months) and no ORR difference in the KRASmutated subgroup (0% vs. 10%). A planned trial of selumetinib in combination with the anti-PD-L1 antibody durvalumab has since been suspended (NCT03004105).
[Uses]

It is a tight-binding, uncompetitive inhibitor of mitogen-activated protein kinase kinases (MEK) 1 and 2 currently in clinical development.
[Definition]

ChEBI: A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-chlorophenyl)amino, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectiv ly. It is a MEK1 and MEK2 inhibitor.
Safety DataBack Directory
[HS Code ]

29349990
Questions And AnswerBack Directory
[Indications and Usage]

Selumetinib, 1 has a chemical name of 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide. It was developed by British company AstraZeneca and is used to treat advanced non-small cell lung cancer (NSCLC). It is mainly used to treat bile duct cancer, colon cancer, NSCLC, etc. Currently, Selumetinib is in stage III clinical trials for treatment of NSCLC.
[Mechanisms of Action]

Selumetinib is the first mitogenextracellular kinase (MEK1/2) inhibitor to be used in thyroid cancer clinical trials. It inhibits extracellular signal regulating kinase (ERK/2) and activates caspase to dramatically inhibit ERK1/2 phosphorylation.
[Clinical Research]

In phase II clinical trials of radioiodine-refractory papillary thyroid carcinoma, 39 patients took daily oral doses of Selumetinib (100mg bid) for 28 days; results showed that 21 patients’ conditions stabilized (54%), 11 patients’ conditions worsened (28%), 49% patients’ conditions were stable for 16 weeks, 36% patients’ conditions were stable for 24 weeks, and survival terms did not progress to 32 weeks. Negative reactions mainly consisted of rashes (59%), diarrhea (44%), and weakness (41%). Some studies found that after treating 20 patients with thyroid cancer with Selumetinib (75mg bid) for 4 weeks, Selumetinib increased the iodine uptake and retention of patients with radioiodine-refractory papillary thyroid carcinoma. In a blind and random comparative study between a Selumetinib and Docetaxel (DOC) combination treatment group and DOC and placebo treatment group for 87 mutant NSCLSC patients, survival times were 9.4 months and 5.2 months, PFS were 5.3 months and 2.1 months, RR were 37% and 0%, thus showing dramatic differences. Selumetinib’s main negative reactions include neutrophil depletion, dermatitis, and respiratory failure.
606143-52-6 suppliers list
Company Name: Jurong Coupling Biotechnology Co., Ltd.
Tel: 13656108824
Fax:
Website: www.chemicalbook.com/ShowSupplierProductsList1832250/0.htm
Company Name: HONG KONG IPURE BIOLOGY CO.,LIMITED
Tel: 86 18062405514 , 18062405514
Fax:
Website: www.chemicalbook.com/ShowSupplierProductsList1523002/0_EN.htm
Company Name: Capot Chemical Co.,Ltd.
Tel: +86-571-85586718 , +86(0)13336195806
Fax: +86-571-85864795
Website: http://www.capotchem.com
Company Name: Nanjing Finetech Chemical Co., Ltd.
Tel: 025-85710122 17714198479
Fax: 025-85710122
Website: www.fine-chemtech.com
Company Name: ATK CHEMICAL COMPANY LIMITED
Tel: +86 21 5161 9050/ 5187 7795
Fax: +86 21 5161 9052/ 5187 7796
Website: www.atkchemical.com
Company Name: career henan chemical co
Tel: +86-0371-55982848
Fax:
Website: www.coreychem.com/index.html
Company Name: GIHI CHEMICALS CO.,LIMITED
Tel: 08657186217390
Fax:
Website: www.gihichemicals.com
Company Name: Hebei Guanlang Biotechnology Co., Ltd.
Tel: +8619930503282
Fax:
Website: https://www.chemicalbook.com/manufacturer/crovell/
Company Name: BOC Sciences
Tel: 1-631-485-4226
Fax: 1-631-614-7828
Website: https://www.chemicalbook.com/ShowSupplierProductsList518419/0.htm
Company Name: Beijing Yibai Biotechnology Co., Ltd
Tel: 0086-182-6772-3597
Fax:
Website: www.chemicalbook.com/ShowSupplierProductsList187389/0.htm
Company Name: Chongqing Chemdad Co., Ltd
Tel: +86-13650506873
Fax:
Website: http://www.chemdad.com/
Company Name: CONIER CHEM AND PHARMA LIMITED
Tel: 86-18523575427
Fax:
Website: http://www.conier.com/
Company Name: Zhuozhou Wenxi import and Export Co., Ltd
Tel: +8613111626072 (WhatsApp)
Fax: Wechat: +8613111626072 Wickr me: waynehu
Website: www.wenxichem-pharma.com
Company Name: Antai Fine Chemical Technology Co.,Limited
Tel: 18503026267
Fax:
Website:
Company Name: Target Molecule Corp
Tel: 781-999-5354 , 18019718960
Fax:
Website: https://www.targetmol.com/
Company Name: Dideu Industries Group Limited
Tel: 029-88380327; 17691182729
Fax:
Website: www.dideu.com
Company Name: AFINE CHEMICALS LIMITED
Tel: 008657185134551
Fax: 008657185134895
Website: www.afinechem.com/index.html
Company Name: Shandong Natural Micron Pharm Tech Co.,LTD
Tel: 13752232623
Fax:
Website: www.nmpharmtech.com
Tags:606143-52-6 Related Product Information
943332-08-9 439081-18-2 2152628-33-4 1195765-45-7 1032900-25-6 849217-68-1 1110813-31-4 1213269-23-8 1197958-12-5 417716-92-8 443913-73-3 391212-29-6 179324-69-7 1032350-13-2 391210-10-9 871700-17-3 183319-69-9 918504-65-1